OUTCOMES IN ELDERLY HODGKIN LYMPHOMA: RESULTS FROM KOREAN MULTICENTER COHORT

Introduction: Hodgkin lymphoma (HL) is a rare disease especially in Asian known to have good prognosis. However, elderly patients (pts), due comorbidities and poorer tolerance treatment, the survival rate not as younger pts. This study aims enhance understanding of current status HL pts Korea. Methods: We analyzed total 159 who were diagnosed between 1999 2018 from 16 medical centers Korea retrospectively. Pts aged 60 years (yrs) or older included clinical data collected. Results: The median age at diagnosis was 69 yrs (range 60–85) male predominant (n = 110, 69.2%). More than half ages 86, 54.1%), 39.6% 63) 70 79 yrs, 6.2% 10) 80 yrs. Forty-eight (30.2%) had least 2 prior malignancy history. Advanced Lugano stage III IV presented 72.3% 115) patients. with absence B symptoms 99, 62.3%), non-bulky 152, 95.6%) bone marrow involvement 109, 68.5%) predominant. Elevation lactate dehydrogenase (LDH) observed 44.0% 70). Most 143, 89.9%) CD30 positive malignant cells. Among pts, 1 cured by radiotherapy alone other 158 received induction chemotherapy. Median 5 cycles doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) most common first (1st) line treatment 148, 93.1%). average dose intensity ABVD 86.7% for each cycle. Average bleomycin dosage 84.9% cycle 41.9% 62) reduced bleomycin. Except 39 whose responses evaluable, response including complete remission partial after 1st therapy 96.7% population. Thirty second (2nd) major cause proceeding 2nd continuous 75, 58.1%). Grade 3, 4 adverse events (AE) 46.8% 74). Cytopenia grade AE. 148 induction, pneumonitis 27.0% 40) among these 55.0% 3-yr progression-free 73.1% (95% confidence interval [CI], 63.38–80.64) 5-yr overall (OS) 65.1% CI 55.53–73.04). symptom (hazard ratio [HR] 1.96, p 0.016), poor performance (HR 1.95, 0.000), elevated LDH 1.17, 0.031), relapse/refractory 1.27, pulmonary AE 2.50, 0.001) factors OS. Keyword: No conflicts interests pertinent abstract.